Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | OLIG2 |
| Gene Name: | OLIG2 |
| Protein Full Name: | Oligodendrocyte transcription factor 2 |
| Alias: | Class B basic helix-loop-helix protein 1;Class E basic helix-loop-helix protein 19;Protein kinase C-binding protein 2;Protein kinase C-binding protein RACK17 |
| Mass (Da): | 32385 |
| Number AA: | 323 |
| UniProt ID: | Q13516 |
| Locus ID: | 10215 |
| COSMIC ID: | OLIG2 |
| Gene location on chromosome: | 21q22.11 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19783 |
| Percent of cancer specimens with mutations: | 0.23 |
| Deregulated in translocations: | T-cell acute lymphoblastic leukemia, fusion partner is TCRA. |
| Normal role description: | OLIG2 is a transcription factor required for motor neuron and oligodendrocyte differentiation and development. OLIG2 functions primarily as a transcriptional repressor and is hypothesized to repress genes which repress neuronal development. Overexpression of OLIG2 has been detected in oligodendroglial tumors which may obliterate regulation of repressors preventing tumour growth. The OLIG2 gene locus was also observed to participate in a translocation event with TCRA which has been implicated in T-cell acute lymphoblastic leukemia. |